Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Wei Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0003-4610-8490; OpenAlex author ID A5100344597. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2014: 3 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 7 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers

Papers 17

  1. Identification of the Genetic Association Between Type-2-Diabetes and Pancreatic Cancer. First author DOI 10.1007/s10528-022-10308-2↗
  2. The Role of Genetic, Metabolic, Inflammatory, and Immunologic Mediators in the Progression of Intraductal Papillary Mucinous Neoplasms to Pancreatic Adenocarci… Co-author DOI 10.3390/cancers15061722↗
  3. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, rand… Co-author DOI 10.1186/s12885-022-09974-7↗
  4. The expression and clinical prognostic value of protein phosphatase 1 catalytic subunit beta in pancreatic cancer. Co-author DOI 10.1080/21655979.2021.1934243↗
  5. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1. Co-author DOI 10.1158/1535-7163.mct-20-0316↗
  6. Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma. First author DOI 10.12998/wjcc.v9.i19.4998↗
  7. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  8. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgic… Co-author DOI 10.1002/cam4.3075↗
  9. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Co-author DOI 10.1002/jmri.27024↗
  10. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.012↗
  11. Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study. Last author DOI 10.1186/s40644-020-0288-3↗
  12. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Co-author DOI 10.18632/oncotarget.27496↗
  13. AMP‑activated protein kinase family member 5 is an independent prognostic indicator of pancreatic adenocarcinoma: A study based on The Cancer Genome Atlas. Co-author DOI 10.3892/mmr.2020.11504↗
  14. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2019.11205↗
  15. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. First author DOI 10.1007/s13277-013-1327-5↗
  16. Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a meta-analysis of 42 observational studies. Co-author DOI 10.1016/j.ejca.2013.08.014↗
  17. Parity and pancreatic cancer risk: evidence from a meta-analysis of twenty epidemiologic studies. Co-author DOI 10.1038/srep05313↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Terence Marques Williams · 4 shared papers, 2020–2021 · strength 0.44
  2. Risheng Que · 3 shared papers, 2020–2022 · strength 0.32
  3. Tingbo Liang · 3 shared papers, 2020–2022 · strength 0.32
  4. Xueli Bai · 3 shared papers, 2020–2022 · strength 0.32
  5. Adam R. Wolfe · 3 shared papers, 2020–2021 · strength 0.31
  6. Mary E. Dillhoff · 3 shared papers, 2020–2021 · strength 0.31
  7. Xiu Hu · 1 shared paper, 2021 · strength 0.28
  8. Meijuan Chen · 1 shared paper, 2023 · strength 0.26
  9. Yaling Liang · 1 shared paper, 2023 · strength 0.26
  10. Haokai Xu · 2 shared papers, 2020–2021 · strength 0.25
  11. Fei Chen · 2 shared papers, 2020–2021 · strength 0.25
  12. Zhengxiang Zhong · 2 shared papers, 2020–2021 · strength 0.25
  13. Xiaoguang Wang · 2 shared papers, 2020–2021 · strength 0.25
  14. Zhuoli Zhang · 2 shared papers, 2020 · strength 0.23
  15. Mengyi Lao · 2 shared papers, 2020–2022 · strength 0.23
  16. Kylie Shockley · 1 shared paper, 2023 · strength 0.22
  17. Zobeida Cruz-Monserrate · 1 shared paper, 2023 · strength 0.22
  18. Somashekar Gopala Krishna · 1 shared paper, 2023 · strength 0.22
  19. Jordan M. Cloyd · 2 shared papers, 2020–2021 · strength 0.21
  20. Anne M. Noonan · 2 shared papers, 2020–2021 · strength 0.21
  21. Laith I. Abushahin · 2 shared papers, 2020–2021 · strength 0.21
  22. Nikhil Sebastian · 2 shared papers, 2020–2021 · strength 0.21
  23. Ryan N. Robb · 2 shared papers, 2020–2021 · strength 0.21
  24. Wendy L. Frankel · 2 shared papers, 2020 · strength 0.20
  25. Xiang Li · 2 shared papers, 2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.